NALTIMA (Naltrexone)50MG – 10 tablets
USD $36.80 Add to cart

NALTIMA (Naltrexone)50MG – 10 tablets

USD $36.80

Each Naltima contains 50 mg Naltrexone 10 tablets. Used to help stop drinking alcohol and using street drugs by decreasing the cravings.

ATC Classification: N07BB04
Active Ingrediant: Naltrexone
Generic Name: NALTIMA
Manufacturer: Sun Pharma
Strength: 50 MG
Dosage Type: Tablet
Packaging Type: Foil in Box
Contains: 10 Tab

Examples of Packages sent

Description

Naltrexone Information

What is this drug used for?

• It is used to help keep you alcohol-free.
• It is used to keep a drug-free state.
• It may be given to you for other reasons. Talk with the doctor.

Possible side effects

Naltrexone may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

All products:

• Feeling nervous and excitable.
• Anxiety.
• Headache.
• Muscle cramps.
• Constipation, diarrhea, stomach pain, upset stomach, throwing up, or feeling less hungry.
• More thirst.
• Trouble sleeping.
• Feeling dizzy, sleepy, tired, or weak.
• Back, muscle, or joint pain.
• Signs of a common cold.
• Tooth pain.

Injection:

• Irritation where the shot is given.
• Nose or throat irritation.
• Dry mouth.

Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment:

All products:

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
• Signs of liver problems like dark urine, feeling tired, not hungry, upset stomach or stomach pain, light-colored stools, throwing up, or yellow skin or eyes.
• Signs of high blood pressure like very bad headache or dizziness, passing out, or change in eyesight.
• New or worse behavior or mood changes like depression or thoughts of suicide.
• Feeling confused.
• Trouble breathing, slow breathing, or shallow breathing.
• Sex problems in men.

Injection:

• Signs of lung or breathing problems like shortness of breath or other trouble breathing, cough, or fever.
• Area that feels hard, blisters, dark scab, lumps, open wound, pain, swelling, or other very bad skin irritation where the shot was given.

Medication Safety Issues

Sound-alike/look-alike issues:

Naltrexone may be confused with methylnaltrexone, naloxone

ReVia may be confused with Revatio

Administration issues:

Vivitrol: For intramuscular (IM) gluteal injection only

Storage/Stability

Injection: Store unopened kit at 2°C to 8°C (36°F to 46°F). Kit may be kept at room temperature of ≤25°C (77°F) for ≤7 days prior to use; do not freeze. Following reconstitution of the suspension, administer immediately.

Tablet: Store at 20°C to 25°C (68°F to 77°F).

Adverse Reactions

>10%:

Cardiovascular: Syncope (≤13%)

Central nervous system: Headache (25%), insomnia (≤14%), sleep disorder (≤14%), dizziness (≤13%), anxiety (12%)

Gastrointestinal: Nausea (33%), vomiting (14%), anorexia (≤14%), change in appetite (≤14%), decreased appetite (≤14%), diarrhea (13%), abdominal pain (11%)

Hepatic: Increased serum transaminases (20%), increased serum aspartate aminotransferase (2% to 14%)

Local: Injection site reaction (69%), tenderness at injection site (45%), induration at injection site (35%), pain at injection site (17%)

Neuromuscular & skeletal: Increased creatine phosphokinase in blood specimen (11% to 39%), asthenia (23%), arthralgia (≤12%), arthritis (≤12%), joint stiffness (≤12%)

Respiratory: Pharyngitis (11%)

1% to 10%:

Central nervous system: Depression (8% to 10%), drowsiness (≤4%), sedated state (≤4%), suicidal ideation (≤1%), suicidal tendencies (≤1%)

Dermatologic: Skin rash (6%)

Gastrointestinal: Xerostomia (5%)

Local: Itching at injection site (10%), bruising at injection site (7%)

Neuromuscular & skeletal: Muscle cramps (8%), back pain (≤6%), back stiffness (≤6%)

Frequency not defined:

Cardiovascular: Acute ischemic stroke, acute myocardial infarction, angina pectoris, atrial fibrillation, cardiac failure, cerebral aneurysm, chest pain, chest tightness, coronary arteriosclerosis, deep vein thrombosis, facial edema, palpitations, pulmonary embolism, unstable angina pectoris

Central nervous system: Abnormal dreams, agitation, alcohol withdrawal syndrome, chills, decreased mental acuity, delirium, disturbance in attention, euphoria, heat exhaustion, irritability, lethargy, migraine, paresthesia, peripheral pain, rigors, seizure

Dermatologic: Diaphoresis, night sweats, pruritus

Endocrine & metabolic: Decreased libido, dehydration, hot flash, hypercholesterolemia, weight gain, weight loss

Gastrointestinal: Abdominal discomfort, acute pancreatitis, cholecystitis, cholelithiasis, colitis, constipation, dysgeusia, flatulence, gastroenteritis, gastroesophageal reflux disease, gastrointestinal hemorrhage, hemorrhoids, increased appetite, paralytic ileus

Genitourinary: Abscess of rectum and/or peri-rectal area, urinary tract infection

Hematologic & oncologic: Decreased platelet count, eosinophilia, leukocytosis, lymphadenopathy

Hepatic: Increased serum alanine aminotransferase

Hypersensitivity: Seasonal allergy

Infection: Tooth abscess

Neuromuscular & skeletal: Muscle spasm, myalgia

Ophthalmic: Blurred vision, conjunctivitis

Respiratory: Bronchitis, chronic obstructive pulmonary disease, dyspnea, laryngitis, nasal congestion, pharyngolaryngeal pain, pneumonia, sinusitis, upper respiratory tract infection

Miscellaneous: Fever

Postmarketing: Anaphylaxis, angioedema, eosinophilic pneumonitis, hepatic insufficiency, hepatitis, hypersensitivity reaction, opioid withdrawal syndrome, retinal artery occlusion, urticaria

Additional information

Active Ingrediant

Generic Name

Alternate Names

, , , , , , , , , , , , , , , , , , , , , , , , , , ,

Strength

Dosage Type

Packaging Type

Brand

Sun Pharma

Reviews

There are no reviews yet.

Be the first to review “NALTIMA (Naltrexone)50MG – 10 tablets”

Your email address will not be published. Required fields are marked *